Efficacy and Safety of Oral Icotrokinra in Moderate-to-Severe Plaque Psoriasis: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis - PubMed
5 hours ago
- #psoriasis
- #icotrokinra
- #meta-analysis
- Oral icotrokinra is a novel interleukin-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis.
- Systematic review and meta-analysis of 5 RCTs (1951 participants) showed significant efficacy of icotrokinra 200 mg once daily vs placebo.
- PASI 75 response rates at Week 16 were 73% for icotrokinra vs 11% for placebo (OR = 22.03, p < 0.0001).
- Higher clearance rates (PASI 90, PASI 100) also significantly favored icotrokinra.
- No significant difference in adverse events, serious adverse events, or infections between icotrokinra and placebo groups.
- Icotrokinra offers rapid and sustained clinical benefit with a safety profile comparable to placebo.
- Represents a promising oral treatment bridging the gap between existing oral therapies and biologics.